

AMENDED FORM 9**NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES**
(or securities convertible or exchangeable into listed securities¹)

Please complete the following:

Name of Listed Issuer: IMAGIN MEDICAL INC. (the "Issuer").Trading Symbol: IME.Date: October 21, 2016.Is this an updating or amending Notice: ☒ Yes ☐ NoIf yes provide date(s) of prior Notices: September 13, 2016.Issued and Outstanding Securities of Issuer Prior to Issuance: 41,372,634.Date of News Release Announcing Private Placement: September 13, 2016.Closing Market Price on Day Preceding the Issuance of the News Release: \$0.105.**1. Private Placement** (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Robert B. Smalley 11 Haysboro Cres SW Calgary, AB T2V 3G1	125,000	\$0.08		s. 2.3(1) of NI 45-106	Nil	Oct. 21/16	
Ronald Worobec 1012 Bonhomme St PO Box 2898 Jasper, AB T0E 1E0	250,000	\$0.08		s. 2.3(1) of NI 45-106	Nil	Oct. 21/16	
Brayden Sutton 44486 Monte Vista Dr Chilliwack, BC V2R 5T2	125,000	\$0.08		s. 2.3(1) of NI 45-106	Nil	Oct. 21/16	
Richard Mills 2585 Miworth Rd West Prince George, BC V2K 5N8	675,000	\$0.08		s. 2.3(1) of NI 45-106	1,916,000	Oct. 21/16	

Orez Ltd. SN BX, PO Box SN170 Southampton, Bermuda Bill Stampfl, President	200,000	\$0.08		BC Instrument 72 503	Nil	Oct. 21/16	
Stephen Simonds 156 Woodvale Road SW Calgary, AB T2W 3L2	375,000	\$0.08		s. 2.3(1) of NI 45-106	Nil	Oct. 21/16	
Reiner Thoni 1002 5th Avenue Box 278 Valemount, BC V0E 2Z0	70,000	\$0.08		s. 2.3(1) of NI 45-106	80,000	Oct. 21/16	
Marvin Glaser 81 Arbour Vista Close NW Calgary, AB T3G 5P5	187,500	\$0.08		s. 2.3(1) of NI 45-106	332,000	Oct. 21/16	
D. Bruce Letvak 841 Pemberton Rd. Victoria, BC V8S 3R5	350,000	\$0.08		s. 2.3(1) of NI 45-106	100,500	Oct. 21/16	
Roger Buckley PH8 9 Boardwalk Drive Toronto, ON M4L 6T1	1,250,000	\$0.08		s. 2.5(1) of NI 45-106	Nil	Oct. 21/16	
Roland Misera 2030 Kaptey Ave Coquitlam BC 3K 1L4	62,500	\$0.08		s. 2.5(1) of NI 45-106	Nil	Oct. 21/16	
Frances Reinders 20 Maple Hill Drive Kitchener, ON	250,000	\$0.08		s. 2.3(1) of NI 45-106	Nil	Oct. 21/16	
Wendy Lesy 3789 Broadwater Road Castlegar, BC V1N 4V4	25,000	\$0.08		s. 2.5(1) of NI 45-106	Nil	Oct. 21/16	
Bob Lunde 1848 W 11th Avenue Vancouver, BC V6J 2C5	337,500	\$0.08		s. 2.3(1) of NI 45-106	109,000	Oct. 21/16	
Karim Mohamedani 5821 Pioneer Avenue Burnaby, BC V5H 2X8	100,000	\$0.08		s. 2.3(1) of NI 45-106	130,000	Oct. 21/16	
Don Nicholson 638 Cliff Road Bowen Island, BC V0N 1G1	40,000	\$0.08		s. 2.5(1) of NI 45-106	60,000	Oct. 21/16	
Manoj Paliwal 319 E. 60th Avenue Vancouver, BC V5X 1Z8	150,000	\$0.08		s. 2.5(1) of NI 45-106	100,000	Oct. 21/16	
Michael Sadhra 10571 Odlin Road Richmond, BC V6X 1E3	250,000	\$0.08		s. 2.3(1) of NI 45-106	140,500	Oct. 21/16	

- (1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.
- (2) Indicate if Related Person.

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$385,800 .
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. General working capital and the advancement of the Company's efforts to develop imaging solutions for the early detection of cancer through the use of endoscopes. .
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: N/A .
4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities. N/A .
5. Description of securities to be issued:
- (a) Class Units comprised of common shares & warrants .
- (b) Number 4,822,500 Units .
- (c) Price per security \$0.08 per Unit .
- (d) Voting rights each common share is entitled to one vote .
6. Provide the following information if Warrants, (options) or other convertible securities are to be issued:
- (a) Number 4,822,500 warrants .
- (b) Number of securities eligible to be purchased on exercise of Warrants (or options) 4,822,500 shares .
- (c) Exercise price \$0.12 if exercised in the first year; and \$0.16 if exercised in the second year .
- (d) Expiry date 24 months after closing .

7. Provide the following information if debt securities are to be issued: **N/A**
- (a) Aggregate principal amount _____ .
 - (b) Maturity date _____ .
 - (c) Interest rate _____ .
 - (d) Conversion terms _____ .
 - (e) Default provisions _____ .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): **See Attached Schedule A.**
 - (b) Cash _____ .
 - (c) Securities _____ .
 - (d) Other _____ .
 - (e) Expiry date of any options, warrants etc. _____ .
 - (f) Exercise price of any options, warrants etc. _____ .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship _____
- NOT APPLICABLE** _____ .
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.). **NOT APPLICABLE**
- _____ .
11. State whether the private placement will result in a change of control.
- There will not be a change of control.** _____ .

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. _____

_____.

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102.

2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: N/A
_____.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: ____
_____.

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

(a) Total aggregate consideration in Canadian dollars: _____.

(b) Cash: _____.

(c) Securities (including options, warrants etc.) and dollar value: _____
_____.

(d) Other: _____.

(e) Expiry date of options, warrants, etc. if any: _____.

(f) Exercise price of options, warrants, etc. if any: _____.

(g) Work commitments: _____.

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: _____.
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: _____.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): _____.
 - (b) Cash _____.
 - (c) Securities _____.
 - (d) Other _____.
 - (e) Expiry date of any options, warrants etc. _____.
 - (f) Exercise price of any options, warrants etc. _____.

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. _____

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. _____

_____.

Certificate Of Compliance


The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated October 21, 2016.

BILL GALINE

Name of Director or Senior Officer



Signature

DIRECTOR

Official Capacity

**SCHEDULE A
TO AMENDED FORM 9**

**IMAGING MEDICAL INC.
FINDERS' FEES – TRANCHE 1**

Name of Finder	Units Sold by Finder		Finders' Fees	
	# of Units placed	\$ Subscribed	8% Warrants ¹	8% Cash
MACKIE RESEARCH CAPITAL CORPORATION #1920 – 1075 W. Georgia Street Vancouver, BC V6E 3C9	540,000	\$43,200.00	43,200	\$3,456.00
CANACCORD GENUITY CORP 2200 – 609 Granville Street Vancouver, BC V7Y 1H2	125,000	\$10,000.00	10,000	\$800.00
PAT GEORGETTI	1,275,000	\$102,000.00	102,000	\$8,160.00
RICHARD MILLS	1,007,500	\$80,600.00	80,600	\$6,448.00
ROLAR CONSULTING INC. 1848 W 11th Avenue Vancouver, BC V6J 2C5	662,500	\$53,000.00	53,000	\$4,240.00
TOTALS	3,610,000	\$288,800.00	288,800	\$23,104.00

(1) Warrants have same terms as warrants comprising part of the Units.